BETHESDA, MdEnrollment has begun in a trial of Neovastat (Aeterna
Laboratories), also known as AE-941, to test the Canadian-produced shark
cartilage extract in patients with unresectable stages IIIA and IIIB
non-small-cell lung cancer (NSCLC) who are undergoing induction chemotherapy
and radiation therapy.
The randomized, double-blind, placebo-controlled study,
supported by the National Cancer Institute, anticipates enrolling 756 patients
within the next 3 years at more than 50 sites in the United States and Canada.